Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 246 results for "biotechnology regulatory authority of..."

Put info in public domain: Jairam Ramesh on GM mustard
DNA India

Put info in public domain: Jairam Ramesh on GM mustard

Ramesh also expressed regret that independent regulator Biotechnology Regulatory Authority of India is still not in place Business Standard, 1 month ago
Put info in public domain: Ramesh on GM mustard Press Trust of India, 1 month ago
[x]  

267 images for biotechnology regulatory authority of india

Financial Express, 2 days ago
Financial Express, 5 days ago
Financial Express, 1 week ago
Indian Express, 1 week ago
Financial Express, 1 week ago
Financial Express, 2 weeks ago
Times of India, 2 weeks ago
Media Nama, 4 days ago
Livemint.com, 5 days ago
Financial Express, 3 weeks ago

Developments in Bio-Technology Sector

India's research performance in Pharmacology and Biotechnology indicates that India's scholarly output based on publication data is nearly 5 % of the world's total in 2014 and showing strong average growth of over 12 % annually. Shri Y.S. Chowdary, ...
 Press Information Bureau3 weeks ago

Drug regulatory system set to get Make in India, ease of doing biz makeover, more

The review of the existing law will be in line with the Make-in-India initiative to facilitate the ease of doing business and enhance the quality and efficacy of pharmaceuticals. The review of the existing law will be in line with the Make-in-India ...
 Financial Express4 weeks ago
Minyanville

MYLAN NV : and Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency

BENGALURU, India, HERTFORDSHIRE, England and PITTSBURGH, July 21, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) announced today that the European Medicines Agency (EMA) has accepted for review, ...
 4 Traders1 month ago Biocon Reports a Strong Q1 FY17  AndhraNews.net1 month ago Mylan & Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency  AndhraNews.net1 month ago Mylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency  Pharma Focus Asia1 month ago
[x]  
Topco.co.za

SA Pharma still attractive for foreign investors

South Africa may have fallen out of favour with many foreign investors, but Indian investor, Lupin a transnational pharmaceutical company that is currently the7 th largest global generics player and the 5 th largest in the US by prescription still ...
 Cape Business News1 month ago Forget Pharmaceuticals Think Immunology and Synthetic Biology  Master Investor1 month ago Indian Government Amends Foreign Direct Investment Policy (July 2016)  Gibson Dunn1 month ago
[x]  

First Indian Pharmacovigilance Day conference to be held in Mumbai

The first Indian Pharmacovigilance Day conference will be held in Mumbai on July 29, 2016. Dr J Vijay Venkatraman, Managing Director and Chief Executive Officer of Oviya MedSafe, a global pharmacovigilance consulting and drug safety services, will ...
 CPhI.cn1 month ago Dr J Vijay Venkatraman to chair first Indian Pharmacovigilance Day conference on July 29 at Mumbai  PharmaBiz1 month ago Indian Pharmacovigilance Day 2016 to be observed in Mumbai on July 29  PharmaBiz2 months ago

Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS® Brentuximab Vedotin for CD30 Expressing Cutaneous T Cell Lymphoma

Few Sec ago Business Wire India Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that the Phase 3 ALCANZA clinical trial evaluating ADCETRIS (brentuximab vedotin) in patients with ...
 India Online.in3 weeks ago Seattle Genetics and Takeda Announce Publication of Final Data from ADCETRIS┬« Brentuximab Vedotin Monotherapy Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Classical Hodgkin Lymphoma in Blood  India Online.in1 month ago

Eurofins Scientific: Growth Momentum Sustained as Strong Q1 Operating Trends Continued in Q2 2016

LUXEMBOURG--( BUSINESS WIRE )--Regulatory News: Eurofins Scientific (Paris:ERF): Revenues of EUR 1,208m in H1 2016 represent a 43.5% increase over the same period in the previous year. Organic growth 9 during the period was over 11%, the ...
 Business Wire3 weeks ago Growth momentum sustained as strong Q1 operating trends continued in Q2 2016  Eurofins Scientific3 weeks ago
[x]  
Business Recorder

Biggest Indian acquisition by a Chinese company: Fosun to buy Gland Pharma for $1.26 billion

Image courtesy: http://builderexhibitions.com/project-image.html Hong Kong: The pharmaceutical arm of Chinese conglomerate Fosun plans to buy a majority stake in India`s Gland Pharma Ltd. for as much as $1.26 billion, in what is being touted as ...
 ZeeNews.com4 weeks ago China's Fosun to buy Indian drugmaker for US$1.26b  Malay Mail4 weeks ago
[x]  

Ipsen's First Half 2016 Results

PARIS--( BUSINESS WIRE )--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven pharmaceutical group, today announced financial results for the first half 2016. The Board of Directors, chaired by Marc de Garidel, met on ...
 Business Wire1 month ago Ipsen 's First Half 2016 Results  Stockwatch1 month ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - biotechnology regulatory authority of india
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less